Athenex announces closing of the sale of its china api business

Buffalo, n.y., nov. 21, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its china subsidiaries, which primarily represent the company's ownership of its active pharmaceutical ingredient (api) manufacturing business in china, to chongqing comfort pharmaceutical inc. (chongqing comfort). chongqing comfort was assigned the rights and obligations under the equity purchase agreement (agreement) entered into in july 2022 by tihe capital (beijing) co. ltd, pursuant to the terms of the agreement.
ATNX Ratings Summary
ATNX Quant Ranking